SCHEMBL918623

SCHEMBL918623

COc1cc(CO)cc(OC)c1C(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.44
RORC P51449 1/20 0.44
FOS P01100 1/20 0.42
TTR P02766 1/20 0.42
JUN P05412 1/20 0.42
NR3C1 P04150 1/20 0.42
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
ALOX15 P16050 4/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
MMP1 P03956 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.39
AKR1B1 P15121 1/20 0.39
ALOX12 P18054 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31484827 0.84 THRB (0.36) THRBRORCFOSTTRJUN
SCHEMBL27758290 0.83 TTR (0.42) THRBRORCFOSTTRJUN
SCHEMBL27930394 0.83 TUBB4A (0.46) FOSTTRJUNAKR1B1TNKS2
SCHEMBL29149128 0.81 HSD17B10 (0.35) THRBRORCFOSTTRJUN
SCHEMBL918818 0.81 FOS (0.39) FOSTTRJUNNR3C1HSD17B1
SCHEMBL4576587 0.81 PTGS2 (0.59) FOSTTRJUNNR3C1HSD17B1
SCHEMBL3810245 0.77 CYP3A4 (0.49) FOSTTRJUNNR3C1HSD17B1
SCHEMBL29022512 0.76 ALDH1A1 (0.38) FOSTTRJUNNR3C1HSD17B1
SCHEMBL14280291 0.76 ALDH1A1 (0.38) FOSTTRJUNNR3C1HSD17B1
SCHEMBL14551477 0.76 FOS (0.43) THRBRORCFOSTTRJUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504367-A Preparation method of benvimod 承德医学院 2025-02-25 CN claimed
CN-115894186-B Synthesis method of benvimod intermediate 济川(上海)医学科技有限公司 2024-03-22 CN claimed
CN-112851506-B Industrial preparation method of 3, 5-dimethoxy-4-alkyl benzyl alcohol 湖北英纳氏生物科技有限公司 2023-06-23 CN claimed
CN-112661611-B Preparation method of benzenediol bioactive substance 武汉英纳氏药业有限公司 2023-04-14 CN claimed
CN-115894186-A Synthetic method of intermediate of limod 济川(上海)医学科技有限公司 2023-04-04 CN claimed
CN-112851506-A Industrial preparation method of 3, 5-dimethoxy, 4-alkyl benzyl alcohol 湖北英纳氏生物科技有限公司 2021-05-28 CN claimed
CN-112661611-A Preparation method of benzenediol bioactive substance 武汉英纳氏药业有限公司 2021-04-16 CN claimed
CN-103992212-B Synthesis method for cis-benvitimod, and applications of cis-benvitimod UNIV HEBEI SCIENCE & TECH 2015-07-01 CN claimed
US-20260091027-A1 STILBENE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF THEDERMA SHANGHAI CO LTD (CN) 2026-04-02 US disclosed
EP-4592271-A1 STILBENE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF Thederma Shanghai Co., Ltd. (CN) 2025-07-30 EP disclosed
WO-2025133100-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE PREPARATION OF TAPINAROF INTERQUIM, S.A. (ES) 2025-06-26 WO disclosed
WO-2025099634-A1 PROCESS FOR PREPARING THE POLYMORPHIC FORM III OF TAPINAROF PROCOS S.P.A. (IT) 2025-05-15 WO disclosed
CN-119504367-A Preparation method of benvimod 承德医学院 2025-02-25 CN disclosed
CN-119504367-A Preparation method of benvimod 承德医学院 2025-02-25 CN disclosed
US-20050059733-A1 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues WELICHEM BIOTECH, INC. 2005-03-17 US disclosed
US-20040102517-A1 Modulators of T- cells, neutrophils, macrophages and their associated cytokines GLAXO GROUP LIMITED (GB) 2004-05-27 US disclosed
US-20030171429-A1 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues WELICHEMBIOTECH INC. (CA) 2003-09-11 US disclosed
CN-1407978-A Anti-inflammatory, psoriasis treatment and protein kinase inhibition using hydroxystilbenes, novel stilbene derivatives and analogues thereof GENHUI CHEN (CA) 2003-04-02 CN disclosed
EP-1248774-A2 POLYHYDROXYSTILBENES AND STILBENE OXIDES AS ANTIPSORIATIC AGENTS AND PROTEIN KINASE INHIBITORS Welichem Biotech Inc. (CA) 2002-10-16 EP disclosed
WO-2001042231-A2 POLYHYDROXYSTILBENES AND STILBENE OXIDES AS ANTISORIATIC AGENTS AND PROTEIN KINASE INHIBITORS WELICHEM BIOTECH INC. (CA) 2001-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059733-A1 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues NFKBIA, IKBKB, IKBKE THRB 2458/4885RORC 438/4885FOS 2936/4885
US-20040102517-A1 Modulators of T- cells, neutrophils, macrophages and their associated cytokines IL2, NFATC1, IFNG THRB 1282/4885RORC 81/4885FOS 883/4885
US-20260091027-A1 STILBENE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF AHR, CYP1B1, ARNT THRB 123/4885RORC 343/4885FOS 525/4885
US-20030171429-A1 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues ROCK1, ROCK2, PTK2 THRB 2024/4885RORC 577/4885FOS 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.